Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis (CLLS) has reported its monthly share capital and voting rights information as of July 31, 2025. The company disclosed a total of 100,325,229 shares in its capital structure and 89,428,630 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CLLS declined 2.26%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $192M at that time.
Data tracked by StockTitan Argus on the day of publication.
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 07/31/2025 | 100,325,229 | 89,428,630 |
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Investor Relation contacts:
Arthur Stril, Chief Financial Officer & Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Attachment
FAQ
What is the total number of shares outstanding for Cellectis (CLLS) as of July 31, 2025?
How many voting rights does Cellectis (CLLS) have as of July 2025?
Why is there a difference between Cellectis (CLLS) total shares and voting rights?
On which exchange is Cellectis (CLLS) stock listed?
